人类SNP将炎症和传染病的不同结果与FOXO3调节的途径联系起来
James C Lee1, Marion Espéli, Carl A Anderson
1Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Cell
|September 17, 2013
概括
一种特定的基因变异 (rs12212067:G等位基因) 影响疾病预后,但不影响易感性. 这种遗传因素调节炎症反应,影响诸如克罗恩病和类风湿关节炎等疾病.
科学领域:
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
- 复杂的疾病 复杂的疾病
背景情况:
- 疾病的预后在个体之间有很大差异,影响患者的治疗结果.
- 这种预后变化的遗传基础在很大程度上仍未被探索.
- 全基因组关联研究 (GWAS) 提供了一种强大的工具,用于调查对疾病过程的遗传影响.
研究的目的:
- 研究遗传因素在确定疾病预后中的作用.
- 识别与疾病结果相关的特定遗传变异.
- 阐明将遗传变异与疾病过程联系起来的分子机制.
主要方法:
- 对现有的全基因组关联研究 (GWAS) 数据的分析.
- 在FOXO3A基因中识别和表征特定的非编码多态 (rs12212067:T > G).
- 研究小等位基因 (G) 对单细胞炎症反应的功能影响.
主要成果:
- 虽然rs12212067的小等位基因 (G) 与疾病易感性无关,但与克罗恩病和类风湿性关节炎的较温和临床过程有关.
- 这种等位基因也与严重疟疾的风险增加有关.
- 小等位基因的携带通过涉及TGFβ1的FOXO3驱动途径限制单细胞中的炎症反应,减少促炎细胞因子 (例如TNFα),增加抗炎细胞因子 (例如IL-10).
结论:
- 已经确定了在不同的疾病中对预后的共同遗传贡献.
- 这种贡献通过FOXO3驱动的途径运行,该途径调节炎症反应.
- 这些发现强调了针对治疗干预以改善疾病结果的治疗途径的潜力.
相关概念视频
Pleiotropy
31.3K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.3K
Exon Recombination
3.1K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon...
Exon shuffling follows “splice frame rules.” Each exon...
3.1K
NF-κB-dependent Signaling Pathway
7.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.7K
Single Nucleotide Polymorphisms-SNPs
14.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.8K
The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129


